Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing…
Certara2024 年 9 月 24 日
Why cancer drug programs need human mass balance studies
Historically, drug programs for oncology and other rapidly fatal diseases didn’t include mass balance studies…
Certara2024 年 9 月 23 日
Certara Launches Early Development Solution to Reduce Failure Rates in Early-Stage Drug Development
New solution offers early-stage developers a dedicated team of experts with combined experience in end-to-end…
Certara2024 年 9 月 19 日
A close examination of BCRP’s role in lactation and methods for predicting drug distribution into milk
The article, authored by Caroline Sychterz, Hong Shen, Yueping Zhang, Michael Sinz, Amin Rostami-Hodjegan, Brian…
Certara2024 年 9 月 18 日
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to…
Certara2024 年 9 月 18 日
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
Abstract Despite recent advances in immunotherapies targeting single tumor-associated antigens, patients with multiple myeloma eventually…
Certara2024 年 9 月 18 日
Towards a Platform Quantitative Systems Pharmacology (QSP) Model for Preclinical to Clinical Translation of Antibody Drug Conjugates (ADCs)
Abstract A next generation multiscale quantitative systems pharmacology (QSP) model for antibody drug conjugates (ADCs)…
Certara2024 年 9 月 18 日
